Market Signal Briefing

The Ethereum Foundation, the non-profit organization that stewards the development of the Ethereum ecosystem, published its mandate on Friday, reaffirming its role and the core pillars of Ethereum.

The Ethereum Foundation’s two stated goals are that Ethereum remains decentralized and that users have a “final say” over their onchain assets and data, while the protocol achieves mass scale, according to the mandate.

Censorship resistance, open source code, privacy, security, and freedom-preserving technology are the core properties of Ethereum that will be upheld, the mandate, the document said.

Source: Ethereum FoundationThe Ethereum Foundation said it will continue to focus on core protocol upgrades, “long-horizon research,” cybersecurity, and providing tooling for Ethereum’s developers, while minimizing its role as much as possible. The mandate said: 

“Our ultimate goal is for Ethereum to pass the walkaway test: its protocol and core application layers become robust and trustless enough that they would continue to reliably function and evolve even if the Foundation and today’s core developers disappeared tomorrow.”The Ethereum Foundation said it aims to focus on tasks that become less necessary over time through a process of subtraction. 

The mandate follows a challenging year for the protocol, with Ethereum co-founder Vitalik Buterin saying that Ethereum’s approach to scaling through layer-2 networks “no longer makes sense,” and that many L2s are centralized projects. 

Buterin says a drastic change in how Ethereum scales is neededButeirn said that many layer-2 networks feature centralized points of control, including private trusted networks and centralized sequencers, and have no plans to transition to a fully decentralized model.

“The original vision of L2s and their role in Ethereum no longer makes sense, and we need a new path,” Buterin said in February. 

Buterin argued that a layer-2 project that boasts a throughput of 10,000 transactions per second (TPS) but relies on a multi-signature bridge to interact with the layer-1 protocol is not scaling the Ethereum ecosystem in a decentralized way.

Instead of acting as scaling layers for Ethereum, the ecosystem’s many layer-2 networks should specialize in a niche such as privacy, identity solutions, finance platforms and social media applications, Buterin said, which drew mixed reactions from L2 projects.

Magazine: Ethereum’s roadmap to 10,000 TPS using ZK tech: Dummies’ guide

Cointelegraph is committed to independent, transparent journalism. This news article is produced in accordance with Cointelegraph’s Editorial Policy and aims to provide accurate and timely information. Readers are encouraged to verify information independently. Read our Editorial Policy https://cointelegraph.com/editorial-policy

Two cryptocurrencies are claiming to be reshaping finance, but only one is positioned to deliver. There's XRP (XRP +0.97%), a fintech coin backed by its issuer, Ripple, and World Liberty Financial (WLFI +0.00%), a governance token backed by the Trump family and some of their allies.

Both projects orbit the theme of merging traditional finance with crypto, but which coin is the better pick for an investment of $1,000 right now?

Image source: Getty Images.

XRP is laying financial infrastructure The best argument in favor of investing in XRP is that Ripple spent more than $2.4 billion on acquisitions of crypto-financial businesses in 2025 alone, assembling a toolkit of financial services targeted at institutions. That ecosystem is something that would take a rival blockchain years to replicate.

Perhaps the most important purchase in that shopping spree was Hidden Road, a crypto prime broker that it bought for $1.2 billion. Prime brokers are financial institutions that offer a full range of services for managing trading and investing. Crypto prime brokers do that in the crypto niche. And by buying Hidden Road, Ripple became the first crypto company to own a global, multi-asset prime broker.

Add the crypto treasury management platform GTreasury and stablecoin payments business Rail, and Ripple's footprint now includes crypto custody and storage, cross-border transaction settlement, and Fortune 500 corporate treasury workflows, not to mention the features and capabilities that are actively in development for the XRP Ledger (XRPL). In other words, there are now quite a few ways that Ripple can market XRP as a solution to financial companies, which will likely lead to their increased demand for XRP, as it's used in the back end of many of the new services.

Today's Change

(

0.97

%) $

0.01

Current Price

$

1.39

Furthermore, U.S. regulators approved spot XRP exchange-traded funds (ETFs) in late 2025, and such ETFs have since pulled in around $1.4 billion in net capital inflows, with Goldman Sachs emerging as the largest institutional holder, at roughly $154 million.

The question for any crypto is what gives it lasting value. XRP has a convincing answer: Real financial rails that institutions are beginning to depend on.

World Liberty Financial isn't worth holding World Liberty Financial presents itself as a decentralized finance (DeFi) protocol bridging traditional finance and crypto. In practice, it's a Trump family business venture with a token attached; 75% of the fees generated by token sales go directly to a company that the Trump family owns a majority share of.

The governance rights that WLFI allegedly confers to its holders are very thin. Outside holders can vote on proposals endorsed by the insiders who also control a large portion of the token's supply, but they can't create their own. In a recent vote, the top nine wallets controlled nearly 60% of voting power. So it's effectively impossible for any new buyer to get a large enough number of tokens to actually influence governance decisions in any meaningful way.

Today's Change

(

0.00

%) $

0.00

Current Price

$

0.00

Meanwhile, 80% of the tokens sold to investors upon WLFI's launch remain locked, and the project's insiders have not disclosed their plans for an unlock timeline. That means that the large majority of the total supply could be unlocked at some point by a governance vote, which would enable mass sales that would drive down the token's price. Among experienced crypto investors, setups like this are typically thought of as deal breakers for potential investments because of how bearish the supply dynamics are for new buyers.

The verdict So is XRP a better investment than World Liberty Financial with $1,000?

Yes, and there's no contest at all. WLFI is uninvestable, while XRP is a leading crypto asset. The risks involved in holding XRP are real -- among them, stiff competition for capital to manage -- but they are structurally quite different from those that WLFI holders are exposed to. Also, there's a lot of technology and business development work that could help to bolster XRP's performance.

Nonetheless, no discussion of the XRP narrative would be complete if it did not mention that approximately 39% of the crypto's supply is not in circulation at present. As part of a long-standing plan, 1 billion XRP are unlocked from escrow each month and made available to Ripple. Most of the time, Ripple ends up locking the majority of the coins distributed back into escrow afterward.

But regardless of how Ripple chooses to use the XRP that gets released from escrow, the point is that investors know about the existence of the unlock process up front, as well as its cadence. Thus, they don't need to worry about insiders potentially making decisions that would dent the price of the asset -- something they'd doubtlessly need to worry about when it comes to WLFI.

Scan QR code to install app

Important DisclaimersFXEmpire is owned and operated by Empire Media Network LTD., Company Registration Number 514641786, registered at 7 Jabotinsky Road, Ramat Gan 5252007, Israel. The content provided on this website includes general news and publications, our personal analysis and opinions, and materials provided by third parties. This content is intended for educational and research purposes only. It does not constitute, and should not be interpreted as, a recommendation or advice to take any action, including making any investment or purchasing any product. Before making any financial decision, you should conduct your own due diligence, exercise your own discretion, and consult with competent advisors. The content on this website is not personally directed to you, and we do not take into account your individual financial situation or needs. The information contained on this website is not necessarily provided in real time, nor is it guaranteed to be accurate. Prices displayed may be provided by market makers and not by exchanges. Any trading or other financial decision you make is entirely your own responsibility, and you must not rely solely on any information provided through the website. FXEmpire does not provide any warranty regarding the accuracy, completeness, or reliability of any information contained on the website and shall bear no responsibility for any trading losses you may incur as a result of using such information. The website may include advertisements and other promotional content. FXEmpire may receive compensation from third parties in connection with such content. FXEmpire does not endorse, recommend, or assume responsibility for the use of any third-party services or websites. Empire Media Network LTD., its employees, officers, subsidiaries, and affiliates shall not be liable for any loss or damage resulting from your use of the website or reliance on the information provided herein.Risk DisclaimersThis website contains information about cryptocurrencies, contracts for difference (CFDs), and other financial instruments, as well as about brokers, exchanges, and other entities trading in such instruments. Both cryptocurrencies and CFDs are complex instruments and involve a high risk of losing money. You should carefully consider whether you understand how these instruments work and whether you can afford to take the high risk of losing your money. FX Empire encourages you to conduct your own research before making any investment decision and to avoid investing in any financial instrument unless you fully understand how it works and the risks involved.

Bittensor has surged 18%, driven by a notable spike in demand that has pushed TAO up the altcoin rankings. The rally appears momentum-driven on the surface, attracting fresh attention from traders.

Bitcoin has been trading within a defined range since early February, repeatedly testing both the upper and lower boundaries, trader Cryptoinsightuk said in a recent podcast.

While range highs often act as areas for potential reversals, they can also become breakout zones if buying pressure strengthens.

Meanwhile, XRP is currently trading near the lower boundary of its range against Bitcoin, a structure that has been in place since late 2024. If support continues to hold, the analyst said the pair could see a bounce from current levels.

XRP dominance is also sitting near the bottom of its broader range, suggesting relative strength could return if buyers step in.

However, the XRP/Ethereum (CRYPTO: ETH) trading pair remains largely directionless, with price moving sideways and showing no confirmed trend.

XRP vs Gold Signals Oversold ConditionsThe XRP-to-Gold chart is attracting particular attention from traders. On the weekly timeframe, the relative strength index (RSI) has moved into oversold territory, a condition that historically occurred near major market bottoms.

Price is also testing a key support level aligned with a major Fibonacci retracement and prior order block.

If the RSI begins to turn upward while support holds, it could signal a potential reversal or period of relative strength for XRP against gold, the analyst said.

Image: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Bitcoin price is once again testing the upper boundary of its trading range near $72,000, where selling pressure has historically emerged.

Summary

Range Resistance: Bitcoin is struggling to break above the $72,000 range high. Rejection Signal: A developing daily wick suggests weakening bullish momentum. Downside Risk: A confirmed rejection could rotate price toward $50,000 support. Bitcoin’s (BTC) price action is currently positioned at a technically significant inflection point as the asset trades near the upper boundary of its established trading range. The $72,000 region has repeatedly acted as strong resistance on the daily timeframe, preventing sustained bullish continuation.

While Bitcoin has attempted to challenge this level again, the latest candles suggest early signs of rejection, indicating that the market may remain locked within its broader consolidation structure.

Bitcoin price key technical points Range-High Resistance: $72,000 continues to cap upward momentum on the daily timeframe. Rejection Signal: A developing rejection wick suggests weakening bullish momentum. Downside Risk: A close below the value area high could trigger a rotation toward lower range support. BTCUSDT (1D) Chart, Source: TradingView Bitcoin’s current price action is centered around the $72,000 range-high resistance, a level that has repeatedly defined the upper boundary of the current market structure. On the daily timeframe, this region represents a major liquidity zone where sellers have consistently stepped in to defend price.

Recent price movement shows Bitcoin attempting to challenge this resistance once again, but the appearance of a rejection wick on the daily candle indicates that buyers may be struggling to maintain control. Rejection wicks often appear when price briefly pushes into a resistance zone but fails to sustain momentum, forcing the market back lower as selling pressure increases.

From a technical perspective, this behavior highlights the importance of the value area high as a confirmation level for market direction. The value area high often acts as a pivot point between bullish continuation and bearish rotation. If Bitcoin closes below this level, it would confirm that the latest attempt to break higher has failed, reinforcing the broader range structure.

Range-bound environments are characterized by price oscillating between key support and resistance levels as liquidity is redistributed across the market. In Bitcoin’s case, the broader range structure remains intact between approximately $50,000 on the downside and $72,000 on the upside.

As long as the range-high resistance continues to hold, the probability favors further rotational price action rather than a sustained breakout. This means the market may gradually move back toward lower support levels in search of liquidity.

If bearish confirmation occurs through a close below the value area high, the next logical downside target becomes the swing low within the range. This would place the broader range support near the $50,000 region back into focus.

The $50,000 level represents a historically significant support zone where strong demand previously emerged. It also marks the lower boundary of the current trading range, making it a key area where buyers may attempt to defend price once again.

Market structure analysis further supports this scenario. When an asset repeatedly fails to break above resistance, it often signals that the market requires additional liquidity before attempting another breakout. This liquidity is typically found at lower levels where stop orders and resting bids accumulate.

Because of this dynamic, rotational movements between range highs and range lows are common in consolidation phases. These cycles allow the market to rebalance supply and demand before a more decisive directional trend eventually forms.

What to expect in the coming price action As long as Bitcoin remains below the $72,000 range-high resistance, the broader range structure is likely to remain intact. A confirmed rejection below the value area high would increase the probability of a rotational move toward the $50,000 range support, while a decisive breakout above resistance would be required to invalidate the bearish outlook.

Prefer Us On Google

Altcoin market momentum may depend on whether Ethereum can reclaim a leadership role after months of inconsistent performance, according to several market trackers.

Research shared by Altcoin Vector suggests that Ethereum has struggled to sustain market leadership since the broader trend shifted. While the asset has occasionally attempted to anchor broader altcoin rotations for XRP, SOL, ADA, BNB, DOGE, SHIB, and the likes, those moves have repeatedly faded before developing into sustained expansions.

Analysts say the pattern reflects a lack of strong relative performance. However, even a temporary recovery in Ethereum’s relative strength could act as the catalyst for an altcoin rally if momentum builds.

Other indicators point to a stronger long-term setup. Analyst CW recently highlighted that Ethereum’s realized capitalization over the past year has turned positive again, a signal historically associated with the start of larger bullish cycles.

According to that analysis, the rally that began around May 2023 could be the early stage of what may become the dominant upward move of the current cycle.

Advertisement  

Some market commentators are even projecting significantly higher long-term valuations. For instance, Crypto Patel argues that extreme upside targets, including a hypothetical move toward $30,000, cannot be dismissed outright given Ethereum’s evolving role in decentralized finance and tokenized assets.

Factors cited include the increasing adoption of AI-related payment infrastructure, potential quantum-resistant design advantages over Bitcoin, and growing institutional interest, such as staking-focused investment products promoted by firms including BlackRock.

Market data from CoinMarketCap shows Ethereum trading near $2,113, up about 2.8% over the past day as the market rose alongside Bitcoin. The recent move was supported by a technical breakout above key moving averages and a significant increase in trading volume.

In the near term, holding the $2,100 level could allow Ethereum to retest resistance around $2,147, while a drop below $2,083 could trigger a short-term pullback.

The Shiba Inu price is trading at $0.0000061, trapped between a sudden surge in deflationary activity and a suffocating macro sentiment backdrop.

As the community successfully removed over 68M tokens from circulation in the last 24 hours, spiking the SHIB burn rate significantly, the token enjoyed a +2.7% pump overnight as the meme coin sector continues to gain momentum.

SHIB burn rate surges +45% — 6.8M+ tokens torched in 24h as Shibarium txs spike & whales keep stacking off exchanges (exchange supply hitting lows). FHE privacy upgrade on track for Q2: full confidential txs + shielded DeFi loading. Ecosystem heating up!#SHIB #ShibArmy pic.twitter.com/yloe1U6Gc5

— Shib Crypto Mind (@ShibMasterMind) March 12, 2026

Traders are now questioning whether this supply shock is enough to counter the broader bearish trend that is pushing meme coins toward critical support levels.

On-chain metrics are now in unison with the SHIB price chart.

For now, the market is deciding whether the burn can continue to fuel this recent momentum or if a reversal signal will flash soon.

(SOURCE: TradingView)

SHIB Burn Rate: Deflation vs. Supply Reality According to data from the tracking platform Shibburn, the Shiba Inu ecosystem aggressively activated its deflationary mechanism over the past day, incinerating a total of 68M SHIB.

This removal represents a substantial uptick in the burn rate, signaling renewed community effort to reduce the asset’s circulating supply. In principle, these burn activities remain the ecosystem’s primary method for engineering crypto deflation, sending tokens to inaccessible “dead” wallets to permanently remove them from the ledger.

However, analysts warn that the sheer scale of the existing supply dampens the impact of these burns. Despite 68M tokens being destroyed, Shiba Inu still has over 585 trillion SHIB in circulation.

While the Shibarium Layer-2 network continues to integrate burn mechanisms into its transaction fee structure to automate this process, the current volume represents a microscopic fraction of the total market cap.

Critically, historical data indicate that burn spikes do not guarantee price appreciation. As noted in previous market cycles, SHIB has seen burn rates surge by thousands of percentage points without triggering a corresponding rally, suggesting that while the mechanism improves tokenomics on paper, it lacks the immediate leverage to overcome bearish market structures.

I'm checking $SHIB weekly chart.

Falling wedge is tightening, a breakout is quite possible. pic.twitter.com/lDG0mKs9OT

— $SHIB KNIGHT (@army_shiba) March 13, 2026

DISCOVER: Next Crypto to Explode in 2026

Shiba Inu Price Analysis: Technical Weakness Persists From a technical perspective, meme coin analysis reveals a precarious setup. SHIB is currently trading above $0.000006, up marginally by +2.7% over the last 24 hours, but still entrenched in a longer-term downtrend. The asset recently bounced from a local low of $0.000005655, but the recovery lacks the volume required to confirm a reversal.

Traders are closely monitoring the immediate resistance at $0.00000650. This level has acted as a ceiling for price action throughout the week.

A failure to reclaim this zone would likely invalidate the short-term bullish thesis derived from the burn news. Conversely, the immediate support sits at $0.00000545, a level that bulls must defend to prevent a slide toward psychological lows.

Momentum indicators paint a neutral-to-bearish picture. The Relative Strength Index (RSI) is hovering at 43.60, indicating that while the asset is not yet in oversold territory, buying momentum is virtually non-existent. The price is also trading below its 50-day Moving Average, a classic indicator of bearish control.

Maxi Doge ($MAXI) $4.6M Presale Momentum Builds as Meme Coins Show Signs of Life While Shiba Inu is helping reignite the meme coin space, Maxi Doge ($MAXI) is emerging as a blue-chip presale alternative, offering a defined entry point through its ongoing ICO phase.

(SOURCE: Maxi Doge)

Unlike SHIB, which is weighed down by trillions of tokens and years of baggage, MAXI offers a fresh start with a clear roadmap. The project has already raised $4.6M capital in its early rounds, signaling strong interest from retail participants seeking high upside absent in mature assets.

For investors hedging against the risk of SHIB stagnation, Maxi Doge presents a speculative vehicle with a distinct risk-reward profile. It is the perfect play for those who missed the initial run-ups on the likes of DOGE, SHIB, and PEPE, all of which printed literal millionaires overnight.

MAXI is currently selling at $0.0002808, with just 48 hours remaining before the presale moves to its next price stage, which will mark the end of this early-bird offering.

VISIT MAXI DOGE PRESALE HERE

EXPLORE: Best Solana Meme Coins to Buy

Disclaimer: Coinspeaker is committed to providing unbiased and transparent reporting. This article aims to deliver accurate and timely information but should not be taken as financial or investment advice. Since market conditions can change rapidly, we encourage you to verify information on your own and consult with a professional before making any decisions based on this content.

Altcoin News

Daniel Frances is a technical writer and Web3 educator specializing in macroeconomics and DeFi mechanics. A crypto native since 2017, Daniel leverages his background in on-chain analytics to author evidence-based reports and deep-dive guides. He holds certifications from The Blockchain Council, and is dedicated to providing "information gain" that cuts through market hype to find real-world blockchain utility.

TL;DR:

The ETHB fund recorded a trading volume of $15.5 million on its opening day, exceeding initial expectations for a product of this nature. BlackRock has set a 0.25% management fee, reduced to 0.12% during the first year or until it reaches $2.5 billion in assets. Coinbase will serve as the primary custodian, delegating staking to specialized validators such as Figment, Galaxy Blockchain Infrastructure, and Attestant. This Friday, the launch of BlackRock’s Staked Ethereum ETF was announced under the ticker ETHB, marking the firm’s first foray into products that capture the Ethereum network’s native yield for institutional investors.

BlackRock's Staked Ether ETF — $ETHB — launched with just over $100 mln in assets. Through ~2pm eastern it has traded about $11.1 mln. Pretty good start for any ETF. pic.twitter.com/vd1gDLDvKR

— James Seyffart (@JSeyff) March 12, 2026 The fund will initially operate with $100 million in assets under management (AUM). Although the $15.5 million volume pales in comparison to the $264 million seen by the spot Ethereum ETF (ETHA), analysts point out that BlackRock’s Staked Ethereum ETF operates under a monthly dividend structure, which attracts a profile of investors focused on cash flow.

The Impact of Staking on ETH Circulating Supply Furthermore, the ETHB structure provides price exposure while also distributing network rewards directly to shareholders. Experts view this mechanism as a bullish catalyst, as every dollar flowing into the fund implies locking Ether into the consensus protocol.

It is worth noting that the launch of this financial vehicle occurs in a context where the price of ETH is hovering around $2,100. By reducing the available supply through institutional staking, a deflationary pressure is created which, combined with growing demand, could redefine the price structure in the medium term.

In summary, the debut of ETHB consolidates the thesis that institutions are not only looking to speculate on price but also want to participate actively in the yield of blockchain infrastructure, validating Ethereum as an income-generating asset.

TL;DR

Versan Aljarrah argues stablecoins serve different functions than XRP in payments. Stablecoins act as digital currency; XRP functions as a liquidity bridge asset. Ripple confirms RLUSD stablecoin complements XRP rather than replacing its role. Versan Aljarrah, founder of Black Swan Capitalist, publicly dismissed concerns that stablecoins could replace XRP within the global digital payments infrastructure. His central argument: both assets serve distinct functions within the same system.

Stablecoins are not replacing XRP.
They’re completing the stack.

Stablecoins represent currency.
XRP represents liquidity.

Together they create programmable settlement.

— Black Swan Capitalist (@VersanAljarrah) March 12, 2026

The debate intensified following the integration of Ripple USD (RLUSD) into Ripple’s payments solution and the growing number of stablecoins issued by institutions like JPMorgan Chase and PayPal.

The Key Difference: Currency vs. Liquidity Bridge Aljarrah drew a clear line between the two assets:

Stablecoins function as digital currency. They maintain a fixed value relative to the dollar or another fiat currency, eliminate price volatility, and allow transactions across blockchain networks. Their adoption expanded across trading, remittances, and decentralized finance. XRP acts as a liquidity bridge. It does not operate as an everyday transaction currency, but as the asset that connects different currencies during the settlement process between financial institutions. From that perspective, both assets complement each other. Stablecoins handle the transaction layer, while XRP supplies the liquidity needed for payments to cross borders quickly and at low cost.

Aljarrah argued that combining both elements enables a programmable settlement infrastructure where digital assets move and settle almost in real time.

The Debate Inside the XRP Community Several community members backed Aljarrah’s position. One user pointed out that stablecoins provide value stability, while XRP solves the liquidity problem in international payments. Together, by that reading, they form a more complete financial infrastructure than either asset delivers on its own.

Skeptics, however, maintain their reservations. The launch of RLUSD — Ripple’s own stablecoin — raised questions about whether the company is gradually shifting XRP away from its historical role as the bridge asset within its payments network.

Ripple responded directly: RLUSD does not replace XRP. According to the company, both assets can function as bridge currencies in cross-border settlements, with RLUSD improving entry points into the system rather than substituting the liquidity function XRP has served since its origin.

The global digital payments market holds room for distinct layers of infrastructure. The real question is not which asset survives, but how each one occupies its place within a financial system that continues to digitize at an accelerating pace.

The AI Trading StrategyThe Financial Times reported on Friday that Max Wojcik, a 29-year-old engineer, feeds weeks of Bitcoin price data into three AI chatbots—Claude, Gemini and ChatGPT. 

He has the chatbots analyze the data together and calculate his probability of winning before he places any five-minute trades.

“Claude is my major brain right now, but I’m still manually placing the trades,” Wojcik said.

The engineer claims to have doubled his money over the past two months using this AI-assisted approach.

Traders flocking to short-term crypto forwards on Kalshi and Polymarket are presented with dashboards showing real-time prices fluctuating around a “price to beat” as a clock counts down toward the end of the contract.

The $70M Daily Volume SurgePolymarket has since added five-minute bets on the same tokens.

These contracts now represent more than half of all crypto trading on both markets. Their growth has created new inefficiencies that sophisticated traders have jumped on, according to Amir Hajian, a researcher at crypto market-maker Keyrock.

“Let’s just call it what it is: these instruments are pure speculation,” Hajian said, noting that ultra-short-duration options were proving particularly popular with retail traders.

The High-Frequency Trading AngleLatency arbitrage had been “rampant” on 15-minute markets before Polymarket introduced a fee last month, Hajian said. 

Sophisticated traders can take advantage of the tiny amounts of time it takes price signals from one exchange to reach another, in this case between Polymarket and crypto exchange Binance.

Large trading firms have continued to target “microstructure inefficiencies” between Polymarket and other exchanges, particularly in five-minute markets. 

Unlike Kalshi, Polymarket does not charge fees on most contracts but added per-trade fees to its 15-minute crypto bets in January.

The company has since announced an expansion of fees of up to 1.56% to all crypto contracts to deter bot-driven arbitrage trading.

The Regulatory ViewCFTC Chair Mike Selig has repeatedly voiced his support for prediction markets, saying last month that event contracts allow investors to hedge risk and manage their wider portfolios.

“Prediction market platforms have managed to take a speculative asset and inject even more mania into its trading,” said Amanda Fischer, policy director at investor advocacy group Better Markets and former chief of staff at the SEC.

The Mainstream AdoptionNasdaq this week filed proposals with U.S. regulators to introduce binary “yes-no” options on whether the tech-heavy Nasdaq 100 index will trade “at, above or below” a predetermined price. 

If approved, Nasdaq’s first “outcome-related options” will expire over a few days, with the exchange potentially considering “zero-day” alternatives with maturity of 24 hours or less.

Image: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Company Reaffirms Strongest Operational Position to Date as Key Development Milestones Advance Company Reaffirms Strongest Operational Position to Date as Key Development Milestones Advance

Commerce.com (CMRC - Free Report) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since analysts are still raising their earnings estimates for the company.

The upward trend in estimate revisions for this company reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool -- the Zacks Rank -- is principally built on this insight.

The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.

For Commerce.com, strong agreement among the covering analysts in revising earnings estimates upward has resulted in meaningful improvement in consensus estimates for the next quarter and full year.

The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:

12 Month EPS

Current-Quarter Estimate RevisionsThe company is expected to earn $0.10 per share for the current quarter, which represents a year-over-year change of +42.9%.

Over the last 30 days, the Zacks Consensus Estimate for Commerce.com has increased 600% because two estimates have moved higher compared to no negative revisions.

Current-Year Estimate RevisionsFor the full year, the earnings estimate of $0.39 per share represents a change of +50.0% from the year-ago number.

In terms of estimate revisions, the trend for the current year also appears quite encouraging for Commerce.com. Over the past month, four estimates have moved higher compared to no negative revisions, helping the consensus estimate increase 440%.

Favorable Zacks RankThe promising estimate revisions have helped Commerce.com earn a Zacks Rank #2 (Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision.

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.

Bottom LineWhile strong estimate revisions for Commerce.com have attracted decent investments and pushed the stock 13.4% higher over the past four weeks, further upside may still be left in the stock. So, you may consider adding it to your portfolio right away.

The buy now, pay later lender has seen its stock plummet on worries about credit losses.

LOS ANGELES, March 13, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming April 13, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Kyndryl Holdings, Inc. (“Kyndryl” or the “Company”) (NYSE: KD) securities between August 7, 2024 and February 9, 2026, inclusive (the “Class Period”).

IF YOU SUFFERED A LOSS ON YOUR KYNDRYL INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS.

What Happened?
On February 9, 2026, Kyndryl announced the Company’s CFO and General Counsel had both departed “effective immediately.” The Company also announced that it would be unable to timely file its quarterly report and that it “is reviewing its cash management practices related disclosures” as well as “the efficacy of the Company’s internal control over financial reporting, and certain other matters following the Company’s receipt of voluntary document requests from the Division of Enforcement of the Securities and Exchange Commission (“SEC”) relating to such matters.”

The Company further announced it “anticipates reporting material weaknesses in the Company’s internal control over financial reporting” which is expected to include at minimum “the effectiveness and strength of certain functions at the Company, including with respect to controls related to information and communication and tone at the top.”

On this news, Kyndryl’s stock price fell $12.90, or 54.9%, to close at $10.59 per share on February 9, 2026, thereby injuring investors.

What Is The Lawsuit About?
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Kyndryls financial statements issued during the Class Period were materially misstated; (2) Kyndryl lacked adequate internal controls and at times materially understated issues with its internal controls; (3) as a result, Kyndryl would be unable to timely file its Quarterly Report on Form 10-Q for the quarter ended December 31, 2025; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

If you purchased or otherwise acquired Kyndryl securities during the Class Period, you may move the Court no later than April 13, 2026 to request appointment as lead plaintiff in this putative class action lawsuit.

Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Charles Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email:  [email protected]
Telephone: 310-201-9150,
Toll-Free: 888-773-9224
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
Charles Linehan
Email:  [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.

LOS ANGELES, March 13, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming April 7, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025, inclusive (the “Class Period”).

IF YOU SUFFERED A LOSS ON YOUR INOVIO INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS.

What Happened?
On August 8, 2024, after market hours, Inovio released its second quarter 2024 financial results, revealing that it expected to submit the Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) for its recurrent respiratory papillomatosis (“RPR”) treatment, INO-3107, in mid-2025, despite previous claims of a mid-2024 submission, due to a “manufacturing issue” with a component of the Company’s proprietary investigational medical device, CELLECTRA.

On this news, Inovio’s stock price fell $0.27, or 3.1%, to close at $8.44 per share on August 9, 2024, thereby injuring investors.

Then, on December 29, 2025, Inovio disclosed that the FDA had accepted the INO-3107 BLA on a standard review timeline rather than the accelerated review timeline that the Company touted the prospects of. The Company further stated that it did not plan to seek approval under the standard review timeline and planned to request a meeting with the FDA to discuss pursuing accelerated approval.

On this news, Inovio’s stock price fell $0.56, or 24.45%, to close at $1.73 per share on December 29, 2025, thereby injuring investors further.

What Is The Lawsuit About?
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) manufacturing for Inovio's CELLECTRA device was deficient; (2) accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107's overall regulatory and commercial prospects were overstated; and (5) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

If you purchased or otherwise acquired Inovio securities during the Class Period, you may move the Court no later than April 7, 2026 to request appointment as lead plaintiff in this putative class action lawsuit.

Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Charles Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email:  [email protected]
Telephone: 310-201-9150,
Toll-Free: 888-773-9224
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
Charles Linehan
Email:  [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. 

NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Five9, Inc. (NASDAQ: FIVN) breached their fiduciary duties to shareholders.

If you currently own Five9 stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].

Why Your Participation Matters:

Shareholder involvement can help improve a company’s policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
One World Trade Center
85th Floor
New York, NY 10007
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]  
https://www.halpersadeh.com

Here Are Ways To Invest And Profit With Cannabis Stocks

3 minute read These Top Marijuana Stocks Could Make The Difference In Your Portfolio The momentum is building once again for marijuana stocks. Since the passing of rescheduling cannabis to class 3, investors are staying sharp. Even though this does not legalize cannabis federally, it brings more relaxed investing without stressing federal issues. The cannabis industry has been undergoing another shift due to this. At the same time, this has led more people to find the best marijuana stocks to buy and hold till the market is up.

Most of the cannabis sector is incredibly volatile, with random changes in trading patterns. Yet in comparison to a few years back, volatile trading has dialed back a bit. But even still, volatility is present and part of the system that allows shareholders to take profits. Right now is a good time to prep and startagizer for the future. Many investors see cannabis stocks as a long-term play as things further develop for the industry.

Meaning companies are working on new products and services that will help meet increased consumer demand. From this, it will show investors that even though the sector still trades at bottom prices, there is potential. The better the business can do, the better the outcome for investors down the road. Below are several marijuana stocks to watch that could be the reason you see big profits in 2026.

Top Marijuana Stocks 2026 GrowGeneration Corp.(NASDAQ:GRWG)
Hydrofarm Holdings Group, Inc.(NASDAQ:HYFM)
The Scotts Miracle-Gro Company. (NYSE:SMG)

GrowGeneration Corp. GrowGeneration Corp., through its subsidiaries, owns and operates retail hydroponic and organic gardening stores in the United States. It operates through two segments, Cultivation and Gardening, and Storage Solutions.

In recent news, the company has announced it will be attending and participating in the 38th Annual ROTH Conference. This event is set to be held on March 22-24, 2026, in Dana Point, California. So at this time, GrowGen will have 1-on-1 meetings during the conference.

Hydrofarm Holdings Group, Inc. Hydrofarm Holdings Group, Inc., together with its subsidiaries, manufactures and distributes hydroponics equipment and supplies for controlled environment agriculture (CEA) in the United States and Canada.

The company has not released any updates since the 2nd week of November 2025. During this time, the company was able to report its Q3 2025 financial earnings.

Highlights And Key Mentions Net sales decreased to $29.4 million compared to $44.0 million. Gross Profit Margin decreased to 11.6% of net sales compared to 19.4%. Adjusted Gross Profit Margin(1) decreased to 18.8% of net sales compared to 24.3%. SG&A expense and Adjusted SG&A(1) expense decreased by 6.8% and 7.4%, respectively. Net loss increased to $16.4 million compared to $13.1 million. [Read More] Marijuana Stocks To Watch In The Stock Market 2026

The Scotts Miracle-Gro Company The Scotts Miracle-Gro Company, together with its subsidiaries, engages in the manufacture, marketing, and sale of products for lawn, garden care, and indoor and hydroponic gardening in the United States and internationally.

At the end of January, the company reported results for the first quarter ended December 27, 2025. The Company also announced that it is in advanced discussions for the sale of its Hawthorne subsidiary to Vireo Growth, Inc.

[Read More] Top Marijuana Penny Stocks to Watch in March 2026

Fiscal 2026 First Quarter Highlights U.S. Consumer net sales were $328.5 million GAAP gross margin rate of 25.0% and non-GAAP adjusted gross margin rate of 25.4% each improved by 90 basis points over prior year GAAP net loss from continuing operations of $0.83 per share and non-GAAP adjusted net loss from continuing operations of $0.77 per share improved by $0.32 and $0.11 per share over prior year, respectively Non-GAAP adjusted EBITDA of $3.0 million improved $2.1 million over prior year Net leverage of 4.03x improved 0.49x versus last year MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | [email protected]

Time to upgrade Arista Networks, Inc. to Buy as AI networking demand accelerates and the company's differentiated platform remains vital to hyperscalers. ANET's hardware/software integration and scale position it to benefit from the AI data center buildout, with FY2026 revenue growth guided above 25%. Despite a premium valuation at 38x forward earnings, ANET's multiple has normalized from prior highs, and price action signals readiness for a new advancing phase.

Omnicom Group Inc. (OMC) Analyst/Investor Day March 12, 2026 9:00 AM EDT

Company Participants

Gregory Lundberg - Senior Vice President of Investor Relations
John Wren - Chairman & CEO
Daryl Simm - Co-President & Co-COO
George Manas - Chief Executive Officer of OMD Worldwide
Ellen Griffin
Deepthi Prakash
Jantzen M. Bridges
Jacki Kelley
Paolo Yuvienco - Executive VP & Chief Technology Officer
Christine Gambino
Philip Angelastro - Executive VP & CFO
Philippe Krakowsky - Co-President, Co-COO & Director

Conference Call Participants

Thomas Yeh - Morgan Stanley, Research Division
Steven Cahall - Wells Fargo Securities, LLC, Research Division
Jason Bazinet - Citigroup Inc., Research Division
Adrien de Saint Hilaire - BofA Securities, Research Division
Julien Roch - Barclays Bank PLC, Research Division
Timothy Nollen - SSR LLC
David Karnovsky - JPMorgan Chase & Co, Research Division
Jason Samwick

Presentation

Gregory Lundberg
Senior Vice President of Investor Relations

Good morning. I'm Greg Lundberg, Head of Investor Relations for Omnicom. Welcome to our Investor Day. You get every year one of these. Thank you for taking the time to be here. A little housekeeping before we get started. Please silence your phone and if you do have to make a call, feel free to step out to the reception area. In the event of an emergency, the venues personnel will be directing us in the closest exits through the doors that you came into today.

A lot of great content today, and we're going to punctuate it with a couple of short breaks. And after all the presentations, we're going to have a Q&A session, and we request that you please hold your questions until then. And now for our disclaimer. Certain of the statements made today may constitute forward-looking statements. These represent our present expectations and relevant factors that could cause actual results to differ materially from those are listed in our SEC filings, including our 2025 Form 10-K. After today's event concludes, an archived webcast of this will

Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around puberty, underscoring importance of early diagnosis and intervention with biologics to help reduce long-term disease burden4-6 Approval marks fourth pediatric indication for Cosentyx, reinforcing its robust safety and efficacy profile1  Basel, March 13, 2026 – Novartis announced today that Cosentyx® (secukinumab) received US Food and Drug Administration (FDA) approval for treating pediatric patients 12 years and older with moderate to severe hidradenitis suppurativa (HS), making it the only IL-17A inhibitor for this population1. The approval of a distinct biologic option for pediatric patients living with HS allows treatment to be tailored to the individual and establishes Cosentyx as a meaningful addition to the treatment landscape1-13.

“Hidradenitis suppurativa (HS) often begins in adolescence and can cause irreversible scarring and disabilities,” said Alexa B. Kimball, MD, MPH, lead investigator of the SUNSHINE and SUNRISE clinical trials in adult HS patients, President and CEO of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center, Boston, and Professor of Dermatology at Harvard Medical School. “The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options.” 

HS is a chronic, systemic inflammatory skin disease that causes recurring boil-like lesions, which can rupture into painful wounds and lead to scarring7. HS affects as many as 1 in 100 people worldwide and often begins around puberty7.  More than half of patients develop symptoms during adolescence, highlighting the importance of early intervention5,6.

“Hidradenitis suppurativa (HS) affects far more than skin; it impacts confidence, emotional well-being and relationships during a formative period for many pediatric patients,” said Brindley Brooks, Founder & CEO, HS Connect. “For families watching their children struggle, this FDA approval brings hope for earlier intervention.” 

The distinct IL-17A mechanism provides physicians with a differentiated therapeutic option to help manage this challenging condition in younger patients, with dosing tailored to patient weight1.  The use of Cosentyx in patients aged 12+ with moderate to severe HS weighing 30 kg or more is supported by well-controlled adult studies and pharmacokinetic modeling extrapolated from adult HS and psoriasis clinical trials, as well as pediatric clinical trial data from other approved indications1. The approval is also supported by dosing analysis, which predicted that weight-based dosing of Cosentyx in pediatric patients can provide similar exposure to adult HS patients1.

“With more than a decade of real-world experience across multiple autoimmune diseases, Cosentyx is a well-established treatment option that many physicians trust,” said Victor Bultó, President, Novartis US. “Yet for young people living with moderate to severe hidradenitis suppurativa (HS), treatment options have remained limited for far too long. Expanding Cosentyx to this population addresses a critical gap in care and underscores our focus on advancing solutions where we can make the greatest impact on outcomes.”   

About Cosentyx® (secukinumab)
Cosentyx is a fully human biologic that directly inhibits interleukin-17A, an important cytokine involved in the inflammation underlying multiple immune-mediated inflammatory diseases. It is approved for use in adults with hidradenitis suppurativa (HS), psoriatic arthritis (PsA), moderate to severe plaque psoriasis (PsO), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA)8-10, as well as in pediatric patients with HS, PsO, enthesitis-related arthritis (ERA), and juvenile psoriatic arthritis (JPsA)11,12. Cosentyx is supported by robust evidence and more than 10 years of real-world data demonstrating its long-term safety and sustained efficacy13-18. Since its launch in 2015, it has been used to treat more than 1.8 million patients worldwide and is now approved in over 100 countries13.

About hidradenitis suppurativa (HS) 
HS is a chronic, systemic, progressive and often painful inflammatory skin disease6,19. It causes recurring boil-like abscesses that can burst, creating open wounds, often in the most intimate parts of the body, which may result in irreversible scarring6,20. It can take up to 10 years on average to get a correct diagnosis, and may affect approximately 1 in 100 people globally6,21. HS impacts patients' quality of life more than any other skin disease, and people living with HS often experience comorbidities such as obesity, diabetes, arthritis and depression20,22, 23.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

References

Cosentyx. Prescribing information. Novartis Pharmaceuticals Corp.  Humira. Prescribing Information. AbbVie Inc. Celltrion, Inc. FDA approves expanded pediatric indications for YUFLYMA® (adalimumabaaty) and unbranded adalimumabaaty in the United States. Press release. Celltrion; October 17, 2025. Available from: https://www.celltrion.com/en-us/company/media-center/press-release/4207. [Last accessed: February 5, 2026].  Ingram JR. The epidemiology of hidradenitis suppurativa. Br J Dermatol. 2020;183(6):990-998. doi:10.1111/bjd.19435  Molina-Leyva A, Cuenca-Barrales C. Adolescent-onset hidradenitis suppurativa: prevalence, risk factors and disease features. Dermatology. 2019;235(1):45-50. doi:10.1159/000493465  Hallock KK, Mizerak MR, Dempsey A, Maczuga S, Kirby JS. Differences between children and adults with hidradenitis suppurativa. JAMA Dermatol. 2021;157(9):1095-1101. doi:10.1001/jamadermatol.2021.2865  MedLine Plus. Hidradenitis suppurativa [online]. Available from: https://medlineplus.gov/genetics/condition/hidradenitis-suppurativa/ [Last accessed: January 2026].  Novartis Europharm Limited. Cosentyx® (secukinumab): Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf [Last accessed: February 2026].  Girolomoni G, Mrowietz U and Paul C. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol 2012; 167: 717-724.  Novartis Cosentyx shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa. [Press release]. Available at: https://www.novartis.com/news/media-releases/novartis-cosentyx-shows-clinically-meaningful-symptom-improvements-patients-hidradenitis-suppurativa-pivotal-phase-iii-trials [Last accessed: February 2026].  Novartis Cosentyx receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis. [Press release]. Available at: https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-treatment-children-and-adolescents-enthesitis-related-arthritis-and-psoriatic-arthritis [Last accessed: February 2026].  Novartis Cosentyx receives positive CHMP opinion for expanded use in childhood arthritic conditions. [Press release]. Available at: https://www.novartis.com/news/media-releases/novartis-cosentyx-secukinumab-receives-positive-chmp-opinion-expanded-use-childhood-arthritic-conditions [Last accessed: February 2026].  Data on file. Cosentyx WW LTD patients Q1'25.  Uta Kiltz et al. Secukinumab Retention and Effectiveness in Patients with PsA and Radiographic Axial Spondyloarthritis: 5-year Final Results of a Prospective Real-world Study. Abstract no:2344. ACR 2024 [Link]  Ippoliti et al. Long-Term Real-World Safety Profile of Secukinumab Assessed Through a 9-Year Experience in Patients Affected by Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Results From a Multicentric Retrospective Study. Dermatologic Therapy. 2025. Article Number: 9618241 [Link]  Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, Pascale P, Delicha EM, Pricop L, Mpofu S. “Secukinumab Provides Sustained Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final 5Year Efficacy and Safety Results from a Phase 3 Trial”. ACR/ARHP 2020 Annual Meeting Abstract. Presented in ACR Open Rheumatology (2020); CONCL00511 (Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study - PubMed)  McInnes IB, Mease PJ, Kivitz AJ, Nash P, Rahman P, Rech J, Conaghan PG, Kirkham B, Navarra S, Belsare AD, Delicha EM, Pricop L, Mpofu S; FUTURE 2 Study Group. “Longterm efficacy and safety of secukinumab in patients with psoriatic arthritis: 5year (endofstudy) results from the phase III FUTURE 2 study.” Lancet Rheumatology. 2020; 2(4): e227–e235. (Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study)  Bissonnette R, Luger T, Thaçi D, Toth D, Lacombe A, Xia S, Mazur R, Patekar M, Charef P, Milutinovic M, Leonardi C, Mrowietz U.Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1507–1514. (Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study) - PubMed)  Garg A, Naik HB, Alavi A, et al. Real-World Findings on the Characteristics and Treatment Exposures of Patients with Hidradenitis Suppurativa from US Claims Data. Dermatol Ther (Heidelb). 2023 Feb;13(2):581-594. doi: 10.1007/s13555-022-00872-1.  Sabat R, Jemec GBE, Matusiak L, et al. Hidradenitis Suppurativa. Nat Rev Dis Primers. 2020;6 18. doi: 10.1038/s41572-020-0149-1.  Kokolakis G, Wolk K, Schneider-Burrus S, et al. Delayed Diagnosis of Hidradenitis Suppurativa and Its Effect on Patients and Healthcare System. Dermatology. 2020;236(5):421-430. doi: 10.1159/000508787  Mac Mahon J, Kirthi S, Byrne N, et al. An Update on Health-Related Quality of Life and Patient-Reported Outcomes in Hidradenitis Suppurativa. Patient Relat Outcome Meas. 2020;11:21-26. doi: 10.2147/PROM.S174299.  Montero-Vílchez T, Sánchez-Díaz M, Martínez-López A, et al. Quality of Life in Patients with Skin Disease and Their Cohabitants. In: Jasneth M, Sage A, Medhane C, Eds. Health-Related Quality of Life. Rijeka: IntechOpen; 2021: Ch. 5.  # # #

Avocado, code name of Meta's next-generation foundational AI model, might not be released until May.

Katelyn is a writer with CNET covering artificial intelligence, including chatbots, image and video generators. Her work explores how new AI technology is infiltrating our lives, shaping the content we consume on social media and affecting the people behind the screens. She graduated from the University of North Carolina at Chapel Hill with a degree in media and journalism. You can reach her at [email protected].

Expertise artificial intelligence, AI image generators, social media platforms

2 min read

Meta's Avocado isn't ripe quite yet. The company has reportedly delayed the release of its next-generation foundational model until May, according to The New York Times, citing unnamed sources. The model has fallen short "on internal tests for reasoning, coding and writing," compared with rival models from Google, OpenAI and Anthropic.

Meta has spent billions of dollars overhauling its efforts to build artificial intelligence models and products, including purchasing a stake in Alexandr Wang's startup for $14.3 billion to make him chief AI officer. The company has poured buckets of cash into hiring top AI engineers last year across its organization. In a January earnings call, Meta confirmed it plans to raise its spending from $72 billion last year to $115 billion to $135 billion, attributing the increase to supporting its AI labs. But all that money hasn't bought the company the results it hoped for, with Google, OpenAI and Anthropic consistently lapping Meta with their newer models.

A Meta spokesperson told CNET, "As we've said publicly, our next model will be good, but more importantly, show the rapid trajectory we're on, and then we'll steadily push the frontier over the course of the year as we continue to release new models. We're excited for people to see what we've been cooking very soon."

That rapid trajectory is key to catch up and keep pace with other AI builders. Google leapfrogged its rivals in November with its Gemini 3 model, showcasing its impressive coding and research abilities. OpenAI was quick to follow with updates to GPT-5. More recently, Claude Code and Cowork from Anthropic have proven to be the most reliable agentic AI available, tools that can handle tasks without human babysitting. However, the biggest AI news from Meta this year is that it's buying Moltbook, a social media platform designed exclusively for AI bots.

Meta has been in the news for other reasons. A renewed wave of privacy concerns has crested over people using smart glasses, particularly the Meta Ray-Ban glasses, to record others without their knowledge or consent. A lawsuit alleges that human staffers behind Meta's smart glasses reviewed footage of people who clearly didn't know they were being recorded, like while they were undressing or having sex. On the social media side of the business, a high-profile trial is debating whether platforms like Meta's Instagram and Facebook are addictive to teens and pose significant health risks.

NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nutex Health, Inc. (NASDAQ: NUTX) breached their fiduciary duties to shareholders.

According to a federal securities lawsuit, Insiders at Nutex Health caused the company to misrepresent or fail to disclose that: (i) HaloMD was achieving lucrative arbitration results for Nutex by engaging in a coordinated scheme to defraud insurance companies; (ii) as a result, to the extent that they were the product of fraudulent conduct, revenues attributable to the Company’s engagement with HaloMD in the IDR process were unsustainable; (iii) in addition, the Company overstated the extent to which it had remediated, and/or its ability to remediate, the material weaknesses in its internal controls over financial reporting; (iv) as a result, the Company was unable to effectively account for the treatment of certain of its stock based compensation obligations; (v) as a result, Nutex improperly calculated these stock based compensation obligations as equity rather than liabilities; (vi) the foregoing increased the risk that the Company would be unable to timely file certain financial reports with the SEC; (vii) accordingly, Nutex’s business and/or financial prospects were overstated; and (viii) as a result, public statements were materially false and misleading at all relevant times.

If you currently own NUTX and purchased prior to August 8, 2024 please contact Justin Kuehn, Esq. by email at [email protected] or call (833) 672-0814.  Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™  

For additional information, please visit Shareholder Derivative Litigation - Kuehn Law.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
[email protected]
(833) 672-0814

FN gains 9% in three months as optical and AI-driven HPC demand power record revenue and growth momentum.

It has been about a month since the last earnings report for Martin Marietta (MLM - Free Report) . Shares have lost about 11% in that time frame, underperforming the S&P 500.

But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Martin Marietta due for a breakout? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent drivers for Martin Marietta Materials, Inc. before we dive into how investors and analysts have reacted as of late.

Martin Marietta Q4 Earnings & Revenues Miss EstimatesMartin Marietta reported lower-than-expected results for the fourth quarter of 2025. The quarterly earnings (from continued operations) and revenues missed the Zacks Consensus Estimate, with the top line growing on a year-over-year basis while the bottom line declining.

The company’s quarterly performance was backed by favorable weather across its business footprint and strong infrastructure activity, with nonresidential construction booming. The Aggregates business thrived during the quarter with strong pricing and increased shipments more than offsetting higher costs. Besides, the company’s portfolio optimization initiative aims at further strengthening the aggregates and asphalt business in the upcoming period.

However, elevated costs marred the bottom-line growth during the quarter, with a weak residential market limiting near-term growth prospects. Nonetheless, Martin Marietta remains well-positioned with its aggregates-led platform and execution of its SOAR 2030 initiatives for the long term, indicating sustained growth and shareholder value.

Inside MLM’s Q4 ResultsThe company reported earnings per share (EPS) from continuing operations of $3.85, which missed the Zacks Consensus Estimate of $4.68 by 17.7%. The metric also tumbled 4% from the year-ago quarter’s EPS (from continuing operations) of $4.03.

Revenues of $1.53 billion also missed the consensus mark of $1.56 billion by 1.9% but increased 9% from the year-ago figure of $1.41 billion.

Consolidated gross margin remained flat year over year at 30% in the reported quarter, with gross profit increasing 10% to $468 million. Adjusted EBITDA from continuing operations was $515 million, up 10% year over year, with adjusted EBITDA margin (from continuing operations) expanding 100 basis points (bps) to 34%.

Martin Marietta’s Segmental DiscussionBuilding Materials reported revenues of $1.4 billion, which grew 4.9% year over year. The segment’s gross margin increased 200 bps year over year to 32% in the quarter.

Within the Building Materials umbrella, revenues from the Aggregates business grew 7.7% to $1.23 billion from the year-ago quarter. Aggregates shipments moved up 2% year over year to 48.9 million tons, with the average selling price (per ton) growing 5% to $23.11. Aggregates’ gross profit per ton increased year over year by 9% to $8.59. Aggregates' gross profit increased 11% to $420 million, with gross margin expanding 100 bps to 34%.

Revenues from Other Building Materials declined 6.1% year over year to $248 million. The gross profit of this business section declined 17.9% year over year to $23 million, with the gross margin contracting 200 bps to 9%. The decline in gross profit was due to the impact of the divestiture of the California paving operations in April 2025.

Specialties reported revenues of $133 million, up 72.7% from $77 million a year ago. The gross margin was down a whopping 700 bps to 22% from 29% a year ago.

Sneak Peek at MLM’s 2025During the year, revenues moved up 9% year over year to $6.15 billion, with EPS from continuing operations tumbling 45% to $16.34.

Gross profit increased 16% to $1.89 billion and the gross margin expanded 200 bps to 31%. Adjusted EBITDA from continuing operations was up 17% year over year to $2.07 billion, with adjusted EBITDA margin expanding 300 bps.

Martin Marietta’s Financial PositionAs of Dec. 31, 2025, Martin Marietta had cash and cash equivalents of $67 million compared with $670 million at 2024-end. It had $1.17 billion of unused borrowing capacity on its existing credit facilities as of 2025-end. Long-term debt (excluding current maturities) was $5.29 billion, at par with the end of 2024 value.

Net cash provided by operations was $1.79 billion at the end of 2025, up from $1.46 billion in the year-ago period. During 2025, MLM returned $647 million to its shareholders, including $197 million in dividend payments and $450 million in share repurchases. As of Dec. 31, 2025, 11 million shares remained under the current repurchase authorization.

Martin Marietta Unveils 2026 GuidanceThe guidance provided is for the continuing operations and excludes any potential impact related to the QUIKRETE transaction.

Martin Marietta expects total revenues between $6.42 billion and $6.78 billion ($6.6 billion at midpoint). Adjusted EBITDA is projected to be between $2.16 billion and $2.31 billion ($2.235 billion at midpoint). Net earnings from continuing operations are anticipated to be between $1.043 billion and $1.158 billion ($1.1 billion at midpoint).

Aggregate shipment is expected to be up between 1% and 3% (2% at midpoint). Total aggregate pricing per ton is anticipated to rise between 4% and 6% (5% at midpoint). Aggregate gross profit is currently expected to be in the range of $1.81-$1.9 billion ($1.855 billion at midpoint).

Other Building Materials’ business section gross profit is projected between $80 million and $110 million ($95 million at midpoint). Specialties’ gross profit is now expected to be between $150 million and $170 million ($160 million at midpoint).

Capital expenditures are now anticipated to be in the range of $550-$600 million ($575 million at midpoint).

How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in fresh estimates.

The consensus estimate has shifted -17.99% due to these changes.

VGM ScoresCurrently, Martin Marietta has a average Growth Score of C, though it is lagging a lot on the Momentum Score front with an F. Following the exact same course, the stock was allocated a grade of F on the value side, putting it in the fifth quintile for this investment strategy.

Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Martin Marietta has a Zacks Rank #5 (Strong Sell). We expect a below average return from the stock in the next few months.